Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of subcutaneous ABBV-951 in people with Parkinson's disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ABBV-951

Snippet

Sponsor: AbbVie | Conditions: Parkinson's Disease (PD) | Phase 1 | Status: COMPLETED